Luspatercept-aamt improved red blood cell transfusion independence with a concurrent hemoglobin increase among certain patients with myelodysplastic syndrome, according to the agent’s manufacturer.
Please provide your email address to receive an email when new articles are posted on . Significantly more patients who received luspatercept vs. epoetin alfa achieved the study’s primary endpoint of ...
The report found the therapy boosted rates of transfusion independence, particularly among patients who had a low baseline transfusion rate. Luspatercept (Reblozyl; Bristol Myers Squibb) can reduce ...
A recent study highlights the effectiveness of Luspatercept in first-line treatment, showing significant patient benefits and ...
Luspatercept shows higher efficacy than ESAs in increasing hemoglobin levels and sustaining improvement in LR-MDS patients. Patients treated with luspatercept achieve faster and more sustained red ...
A recent post‑hoc analysis of the COMMANDS trial evaluated the benefits of Luspatercept versus Epoetin alfa (EA) in ESA‑naïve ...
The first-in-class erythroid maturation agent luspatercept (Reblozyl) is already approved for the treatment of anemia in adult patients with beta thalassemia who require red blood cell (RBC) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback